Hypertensive Disorders in Pregnancy Contemporary Pathophysiology, Clinical Classification, Protocolized Management

1. Warhekar Prathmesh Sudhakar

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

Abstract

Hypertensive disorders of pregnancy remain a primary cause of global maternal morbidity, perinatal mortality, and long-term cardiovascular sequelae. These conditions represent a spectrum of disease states ranging from chronic hypertension and gestational hypertension to preeclampsia, eclampsia, and preeclampsia superimposed on chronic hypertension. Underpinning the disease spectrum is a failure of normal physiological spiral artery remodeling during early placentation, which creates a hypoxic, ischemia-reperfusion placental bed. Sub-placental hypoxia drives the release of antiangiogenic factors, primarily soluble fms-like tyrosine kinase 1 and soluble endoglin, into the maternal circulation. These factors bind to and neutralize vascular endothelial growth factor and placental growth factor, inducing widespread maternal systemic endothelial dysfunction, microvascular vasospasm, and end-organ dysfunction. Diagnostic criteria have evolved from relying solely on new-onset proteinuria to a comprehensive evaluation of maternal multiorgan involvement, including acute kidney injury, liver dysfunction, neurological impairment, hematological derangements, and fetal growth restriction. The integration of angiogenic biomarkers, specifically the ratio of soluble fms-like tyrosine kinase 1 to placental growth factor, has transformed clinical triage by providing high negative predictive value for ruling out preeclampsia in symptomatic women. Management strategies prioritize risk reduction through early-gestation low-dose aspirin prophylaxis, rigid blood pressure control using evidence-based antihypertensive regimens, seizure prevention using magnesium sulfate, and timed delivery based on gestational age and disease severity. While delivery represents the definitive treatment for placental pathology, the systemic maternal endothelial insult persists beyond the puerperium, predisposing affected women to a significantly elevated lifetime risk of ischemic heart disease, stroke, chronic hypertension, and metabolic syndrome. This comprehensive article synthesizes the current physiological understanding, diagnostic pathways, clinical management frameworks, and dual maternal-fetal outcomes associated with hypertensive disorders across the pregnancy continuum.

Introduction

Hypertensive disorders in pregnancy represent a formidable clinical challenge in modern obstetrics, affecting approximately eight to ten percent of all gestations globally. This group of medical conditions includes chronic hypertension, gestational hypertension, preeclampsia, eclampsia, and preeclampsia superimposed on chronic hypertension. Together, they account for a substantial proportion of direct maternal deaths worldwide, while also driving rates of iatrogenic preterm birth, intrauterine growth restriction, placental abruption, and perinatal death. Although significant progress has been made in critical care obstetrics, peripartum monitoring, and neonatal survival, the global burden of hypertensive disorders in pregnancy remains high, particularly in resource-limited settings where delayed diagnosis and inadequate access to emergency care compound disease severity.

The physiological hallmark of normal human pregnancy involves profound cardiovascular adaptation, including marked plasma volume expansion, systemic vasodilation, elevated cardiac output, and a physiological fall in systemic vascular resistance. In contrast, hypertensive disorders in pregnancy are characterized by a failure of vascular adaptation, heightened vascular reactivity, diminished plasma volume, and progressive systemic endothelial injury. Historically viewed as a transient disorder of elevated blood pressure that resolves following the delivery of the placenta, contemporary cardiovascular research demonstrates that preeclampsia is a dynamic multisystem syndrome with profound long-term consequences. Pregnant women who develop preeclampsia exhibit underlying cardiovascular vulnerability that, when unmasked by the metabolic and vascular stress of pregnancy, translates into a multifold increase in lifetime risk for chronic hypertension, coronary artery disease, heart failure, stroke, and vascular dementia.

Over the past decade, major advances in reproductive immunology, vascular biology, and molecular genetics have altered the diagnostic and therapeutic approach to gestational hypertension. The identification of circulating antiangiogenic proteins released by the ischemic placenta has bridged the gap between early placental malperfusion and late maternal systemic end-organ collapse. Simultaneously, clinical trials evaluating first-trimester screening algorithms, universal low-dose aspirin prophylaxis, aggressive blood pressure targets, and point-of-care angiogenic biomarker assays have refined clinical management. This review provides a detailed synthesis of the pathophysiological mechanisms, diagnostic criteria, evidence-based management strategies, and long-term maternal-fetal health outcomes associated with hypertensive disorders of pregnancy.

Pathophysiology and Vascular Biology

The pathophysiology of hypertensive disorders in pregnancy, particularly preeclampsia, is classically conceptualized as a two-stage disease process. Stage one involves defective endovascular trophoblast invasion and incomplete spiral artery remodeling during the first and early second trimesters of pregnancy. In a normal gestation, specialized extravillous trophoblasts invade the maternal decidua and myometrium, replacing the endothelial lining and muscular tunica media of the high-resistance, low-capacity maternal spiral arteries. This remodeling converts these vessels into large-caliber, low-resistance, high-flow conduits that guarantee abundant, uninterrupted blood flow to the developing intervillous space. In women who subsequently develop preeclampsia, this trophoblastic invasion is incomplete, remaining confined to the superficial decidual segments of the spiral arteries. Consequently, the myometrial segments retain their smooth muscle coat and adrenergic responsiveness, resulting in impaired placental perfusion, localized hypoxia, and oxidative stress within the villous tissue.

Stage two of the disease process represents the clinical manifestation of maternal systemic disease, triggered by the release of soluble placenta-derived factors into the maternal systemic circulation in response to chronic placental ischemia and hypoxia-reperfusion injury. Under hypoxic conditions, the ischemic placenta upregulation and secretes excessive amounts of antiangiogenic factors, most notably soluble fms-like tyrosine kinase 1, a splice variant of the vascular endothelial growth factor receptor 1, and soluble endoglin, a co-receptor for transforming growth factor-beta. Soluble fms-like tyrosine kinase 1 circulates in high concentrations within the maternal blood, where it acts as a molecular sink, avidly binding and neutralizing free circulating vascular endothelial growth factor and placental growth factor. Vascular endothelial growth factor and placental growth factor are essential for maintaining normal endothelial cell homeostasis, fenestration integrity, and baseline nitric oxide production across maternal vascular beds.

The systemic neutralization of vascular endothelial growth factor and placental growth factor by excess soluble fms-like tyrosine kinase 1 leads to severe maternal systemic endothelial dysfunction, microvascular vasospasm, and capillary leak. Endothelial cells lose their ability to produce vasodilator substances, such as nitric oxide and prostacyclin, while upregulating the production of potent vasoconstrictors, including endothelin-1 and thromboxane A2. This imbalance promotes systemic vasoconstriction, increased total peripheral resistance, and progressive elevation of blood pressure. In the kidneys, endothelial injury manifests as classic glomerular endotheliosis, characterized by endothelial cell swelling, loss of endothelial fenestrations, and occlusion of capillary lumens. Glomerular endotheliosis impairs the glomerular filtration barrier, resulting in a decline in glomerular filtration rate, elevated serum uric acid levels, and leakage of plasma proteins into the urine.

Beyond renal involvement, systemic endothelial injury and microvascular thrombosis affect multiple maternal organ systems. In the liver, sinusoidal fibrin deposition and microvascular ischemia cause hepatocellular necrosis, manifesting clinically as elevated serum transaminases, right upper quadrant abdominal pain, and, in severe cases, subcapsular hepatic hematoma or hepatic rupture. In the central nervous system, loss of cerebral autoregulation combined with endothelial breakdown leads to hyperperfusion, vasogenic edema, and capillary microhemorrhages, primarily within the posterior parietal-occipital regions. This posterior reversible encephalopathy syndrome accounts for the neurological symptoms of severe preeclampsia, including intractable headache, visual scotomata, cortical blindness, hyperreflexia, clonus, and eclamptic seizures. In the hematological system, platelet activation and endothelial interaction lead to platelet consumption, resulting in severe thrombocytopenia, while microangiopathic hemolytic anemia develops as red blood cells are fragmented when passing through microvascular networks occluded by fibrin meshes.

The pathophysiology of chronic hypertension and gestational hypertension differs subtly from that of pure preeclampsia, though overlap exists. Chronic hypertension represents pre-existing vascular or essential hypertension that antedates the pregnancy or presents prior to twenty weeks of gestation. Gestational hypertension involves new-onset systemic arterial hypertension arising after twenty weeks of gestation without the accompanying multiorgan manifestations, proteinuric disease, or antiangiogenic plasma profiles characteristic of preeclampsia. However, gestational hypertension shares early hemodynamic traits with preeclampsia, and up to a third of women initially diagnosed with gestational hypertension subsequently progress to full-spectrum preeclampsia as gestation advances, highlighting the shared underlying vascular susceptibility.

Diagnostic Criteria and Biomarker Integration

The diagnostic classification for hypertensive disorders in pregnancy has been refined by major international bodies, including the American College of Obstetricians and Gynecologists and the International Society for the Study of Hypertension in Pregnancy. Hypertension in pregnancy is universally defined as a systolic blood pressure of one hundred and forty millimeters of mercury or greater, or a diastolic blood pressure of ninety millimeters of mercury or greater, measured on two separate occasions at least four hours apart using an appropriately sized arm cuff and a standardized technique. Severe hypertension is defined as a systolic blood pressure of one hundred and sixty millimeters of mercury or greater, or a diastolic blood pressure of one hundred and ten millimeters of mercury or greater, confirmed over a short interval of fifteen to thirty minutes to avoid delays in initiating life-saving antihypertensive therapy.

Chronic hypertension is diagnosed when elevated blood pressure is documented prior to pregnancy or before twenty weeks of gestation, or when hypertension persists beyond twelve weeks postpartum. Gestational hypertension is characterized by new-onset hypertension developing after twenty weeks of gestation in a previously normotensive woman, without systemic multiorgan manifestations or proteinuria, and resolving within twelve weeks after delivery. Preeclampsia is diagnosed when new-onset hypertension after twenty weeks of gestation is accompanied by proteinuria or, in the absence of proteinuria, by evidence of maternal end-organ dysfunction or uteroplacental compromise.

Proteinuria is defined as the excretion of three hundred milligrams or more of protein in a twenty-four-hour urine collection, a protein-to-creatinine ratio of zero point three milligrams per milligram or greater in a random spot urine sample, or a dipstick reading of two plus or greater if quantitative methods are unavailable. Modern diagnostic criteria emphasize that proteinuria is no longer mandatory for a definitive diagnosis of preeclampsia. Preeclampsia is established when new-onset hypertension occurs after twenty weeks of gestation alongside any of the following features of maternal end-organ dysfunction: hematological impairment, defined as a platelet count below one hundred thousand per microliter; renal insufficiency, defined as a serum creatinine concentration exceeding one point one milligrams per deciliter or a doubling of baseline values in the absence of other renal disease; hepatic involvement, defined as serum transaminase concentrations elevated to twice the upper limit of normal; neurological signs, including severe, persistent, treatment-resistant headache, visual disturbances, or eclampsia; or pulmonary edema. Uteroplacental dysfunction, manifesting as severe fetal growth restriction or abnormal umbilical artery Doppler velocimetry, is also recognized as an qualifying diagnostic criterion by international guidelines.

Eclampsia is defined as the onset of new, grand mal tonic-clonic seizures in a woman with preeclampsia, in the absence of other neurological conditions such as epilepsy, intracranial hemorrhage, or space-occupying lesions. Preeclampsia superimposed on chronic hypertension occurs when a woman with pre-existing chronic hypertension develops new-onset proteinuria after twenty weeks of gestation, or experiences a sudden escalation in blood pressure accompanied by new end-organ dysfunction, such as thrombocytopenia, elevated liver enzymes, or acute renal impairment. HELLP syndrome—characterized by hemolysis, elevated liver enzymes, and low platelet count—represents a severe variant of preeclampsia associated with high rates of maternal mortality, disseminated intravascular coagulation, hepatic hematoma, and placental abruption.

The integration of circulating angiogenic biomarkers has revolutionized the clinical evaluation and triage of women presenting with suspected preeclampsia. The ratio of soluble fms-like tyrosine kinase 1 to placental growth factor in maternal serum serves as a direct readout of placental antiangiogenic output and vascular distress. Clinical trials have validated the diagnostic utility of the ratio, demonstrating that a threshold of thirty-eight or lower possesses a negative predictive value of nearly ninety-nine percent for ruling out the development of preeclampsia within one to four weeks in women presenting between twenty and thirty-six weeks of gestation. Conversely, significantly elevated ratios correlate with early-onset severe preeclampsia, adverse maternal-fetal outcomes, and the necessity for delivery within short timeframes. Incorporating these biomarkers into clinical workflows allows clinicians to safely reduce unnecessary hospitalizations for low-risk patients while intensifying surveillance and directing resources toward high-risk women requiring tertiary-level care.

Clinical Management and Interventions

The clinical management of hypertensive disorders in pregnancy requires balancing maternal safety against fetal gestational maturity. The definitive cure for preeclampsia remains the delivery of the placenta, which eliminates the primary source of antiangiogenic factors and placental ischemia. However, immediate delivery at early preterm gestations carries risks of neonatal mortality and long-term neurodevelopmental disability from extreme prematurity. Consequently, management strategies are structured around gestational age, disease severity, maternal hemodynamic stability, and fetal surveillance findings.

Prevention of preeclampsia remains a primary goal in clinical obstetrics. Screening algorithms conducted in the first trimester combine maternal demographic risk factors, mean arterial pressure, uterine artery Doppler pulsatility index, and serum placental growth factor levels to identify women at high risk for developing early-onset preeclampsia. For women categorized as high risk, daily administration of low-dose aspirin, ranging from seventy-five to one hundred and fifty milligrams initiated before sixteen weeks of gestation and continued until thirty-six weeks, significantly reduces the incidence of preterm preeclampsia, fetal growth restriction, and perinatal mortality. Aspirin functions by inhibiting platelet cyclooxygenase-1, thereby shifting the systemic intravascular balance away from pro-inflammatory, vasoconstrictive thromboxane A2 production toward vasodilatory prostacyclin.

In patients with established chronic or gestational hypertension, non-severe target blood pressure management has evolved based on evidence from landmark randomized controlled trials, such as the Control of Hypertension in Pregnancy Study and the Chronic Hypertension and Pregnancy trial. Managing mild-to-moderate hypertension to achieve a target diastolic blood pressure of eighty to eighty-five millimeters of mercury and a systolic blood pressure below one hundred and forty millimeters of mercury significantly lowers the rate of progression to severe hypertension, maternal ICU admissions, and severe preeclampsia without increasing the incidence of small-for-gestational-age birth weight or adverse fetal outcomes. Oral antihypertensive agents considered safe and effective during pregnancy include labetalol, a combined alpha- and beta-adrenergic blocker; extended-release nifedipine, a dihydropyridine calcium channel blocker; and methyldopa, a centrally acting alpha-2 adrenergic agonist. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor antagonists are strictly contraindicated throughout pregnancy due to their documented teratogenicity, causing fetal renal dysgenesis, oligohydramnios, neonatal renal failure, and skull hypoplasia.

Severe hypertension, defined as a systolic blood pressure of one hundred and sixty millimeters of mercury or greater or a diastolic blood pressure of one hundred and ten millimeters of mercury or greater, constitutes an acute hypertensive emergency that requires immediate pharmacological reduction to prevent maternal intracranial hemorrhage, stroke, acute heart failure, and placental abruption. First-line parenteral and oral agents for acute severe hypertension include intravenous labetalol administered as escalating boluses, oral immediate-release nifedipine capsules, or intravenous hydralazine. The clinical goal of acute therapy is not to normalize blood pressure rapidly, but rather to lower systolic pressure to between one hundred and forty and one hundred and fifty millimeters of mercury and diastolic pressure to between ninety and one hundred millimeters of mercury, thereby avoiding maternal hypotension and secondary uteroplacental hypoperfusion.

Magnesium sulfate is the anticonvulsant agent of choice for both the prevention of eclampsia in women with preeclampsia with severe features and the treatment of eclamptic seizures, performing superiorly to phenytoin, diazepam, or lytic cocktails. Magnesium sulfate acts as a central neuroprotective agent, blocking N-methyl-D-aspartate receptors, reducing cerebral vasospasm, and preserving blood-brain barrier integrity. The standard regimen consists of a four-to-six-gram intravenous loading dose administered over fifteen to twenty minutes, followed by a continuous intravenous maintenance infusion of one to two grams per hour for twenty-four hours postpartum or following the last eclamptic seizure. Because magnesium is cleared by the kidneys, clinical monitoring of patellar reflexes, respiratory rate, and urine output is mandatory to prevent magnesium toxicity. Impaired deep tendon reflexes represent an early sign of hypermagnesemia, whereas respiratory depression and cardiac conduction blockade occur at higher plasma concentrations. Calcium gluconate must be available at the bedside as a direct antagonist for magnesium toxicity.

The timing of delivery is governed by gestational age and the presence of severe disease features. In women with gestational hypertension or preeclampsia without severe features, expectant management with close outpatient or inpatient monitoring is maintained until thirty-seven weeks of gestation, at which point delivery is indicated to prevent maternal complications without incurring neonatal prematurity risks. For women presenting with severe preeclampsia at or beyond thirty-four weeks of gestation, or at any gestational age when maternal or fetal stability is compromised, delivery is indicated following maternal stabilization. In women with severe preeclampsia between twenty-four and thirty-four weeks of gestation who remain stable without acute end-organ failure, expectant management in a tertiary care center may be considered to allow for the administration of antenatal corticosteroids, such as betamethasone or dexamethasone, to accelerate fetal lung maturation and reduce the risks of respiratory distress syndrome, intraventricular hemorrhage, and neonatal death. Absolute maternal and fetal contraindications to expectant management at any gestational age include eclampsia, uncontrolled severe hypertension, refractory pulmonary edema, acute kidney injury, disseminated intravascular coagulation, HELLP syndrome, suspected placental abruption, and non-reassuring fetal heart rate patterns.

Maternal and Fetal Outcomes

Hypertensive disorders in pregnancy exert a profound impact on immediate maternal and perinatal survival, while also programming long-term chronic disease trajectories for both mother and child. Immediate maternal complications arising from severe preeclampsia and eclampsia include hemorrhagic stroke, posterior reversible encephalopathy syndrome, cortical blindness, pulmonary edema, acute tubular necrosis, hepatic rupture, and peripartum hysterectomy secondary to severe coagulopathy or placental abruption. In low-resource global environments, eclampsia remains a major direct cause of maternal mortality, primarily resulting from unwitnessed status epilepticus, intracranial hemorrhage, and respiratory failure.

Perinatal outcomes are heavily influenced by the degree of placental insufficiency and the necessity for preterm intervention. Placental hypoperfusion leads to chronic intrauterine hypoxia, which triggers a adaptive physiological response in the fetus, including blood flow redistribution to vital organs such as the brain, heart, and adrenal glands, at the expense of peripheral tissue, renal, and splanchnic perfusion. Clinically, this manifests as fetal growth restriction, oligohydramnios, and abnormal Doppler velocimetry showing elevated umbilical artery resistance, absent or reversed end-diastolic flow, and compensatory redistribution in the middle cerebral artery. Severe cases culminate in intrauterine asphyxia, elevated risk of stillbirth, and emergency cesarean delivery for acute fetal distress. Neonates born to mothers with severe preeclampsia suffer high rates of prematurity-related complications, including respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage, sepsis, and long-term neurodevelopmental delay.

Over the last two decades, clinical follow-up studies have established that preeclampsia is an independent predictor of premature cardiovascular and metabolic disease later in life. Women with a history of preeclampsia face a two- to four-fold increased risk of developing chronic hypertension, ischemic heart disease, myocardial infarction, ischemic stroke, venous thromboembolism, and type 2 diabetes mellitus compared to women with normotensive pregnancies. The risk is particularly elevated in women who experienced early-onset preeclampsia, recurrent preeclampsia in subsequent gestations, or preeclampsia complicated by fetal growth restriction. Pregnancy serves as a stress test for the maternal cardiovascular system, unmasking subclinical metabolic syndrome, endothelial dysfunction, and vascular inflammation. The persistent vascular changes observed years postpartum include increased carotid intima-media thickness, impaired flow-mediated vasodilation, chronic low-grade inflammation, and persistent microvascular rarefaction.

The long-term health implications extend to the offspring exposed to a hypertensive uterine environment. The developmental origins of health and disease paradigm indicates that fetal exposure to placental ischemia, antiangiogenic proteins, maternal inflammation, and intrauterine growth restriction leads to permanent epigenetic and structural alterations in developing organ systems. Offspring born to pregnancies complicated by preeclampsia display higher blood pressure levels in childhood and adolescence, altered cardiac architecture, increased arterial stiffness, and an elevated risk of developing metabolic syndrome, stroke, and cardiovascular disease in adult life. Furthermore, children born preterm due to severe maternal preeclampsia face elevated risks of long-term neurocognitive deficits, educational difficulties, and motor impairments compared to age-matched term controls.

Conclusions

Hypertensive disorders in pregnancy remain a major cause of maternal and perinatal morbidity and mortality worldwide. The pathophysiological paradigm has evolved from viewing preeclampsia simply as gestational hypertension with proteinuria to understanding it as a complex multisystem antiangiogenic disorder driven by placental ischemia and systemic endothelial destruction. Modern diagnostic criteria prioritize maternal end-organ dysfunction and uteroplacental compromise over isolated proteinuria, while angiogenic biomarkers, such as the soluble fms-like tyrosine kinase 1 to placental growth factor ratio, offer objective tools for clinical risk stratification and short-term prediction. Evidence-based management relies on early first-trimester risk screening, low-dose aspirin prophylaxis, blood pressure control, magnesium sulfate for seizure prevention, and timed delivery based on gestational age and disease severity. Recognizing that a pregnancy complicated by hypertension serves as a critical early indicator of future cardiovascular disease, clinical care must extend beyond the puerperium to encompass lifelong cardiovascular risk factor monitoring, lifestyle modifications, and proactive health management for affected mothers and their children.

References

1.     American College of Obstetricians and Gynecologists. (2020). Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics & Gynecology, 135(6), e237–e260. https://doi.org/10.1097/AOG.0000000000003891 Cited by: 1250

2.     Chappell, L. C., Cluver, C. A., Kingdom, J., & Tong, S. (2021). Pre-eclampsia. The Lancet, 398(10297), 341–354. https://doi.org/10.1016/S0140-6736(20)32335-7 Cited by: 480

3.     Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., Ishaku, S., & International Society for the Study of Hypertension in Pregnancy (ISSHP). (2018). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension, 72(1), 24–43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803 Cited by: 1820

4.     Tsetsarkin, Y., Tătaru-Copos, A., & Karpova, N. S. (2023). Literature review: The sFlt1/PlGF ratio and pregestational maternal comorbidities: New risk factors to predict pre-eclampsia. International Journal of Molecular Sciences, 24(7), 6744. https://doi.org/10.3390/ijms24076744 Cited by: 38

5.     Rana, S., Lemoine, E., Granger, J. P., & Karumanchi, S. A. (2019). Preeclampsia: Pathophysiology, challenges, and perspectives. Circulation Research, 124(7), 1094–1112. https://doi.org/10.1161/CIRCRESAHA.118.313276 Cited by: 950

6.     Magee, L. A., Nicolaides, K. H., & von Dadelszen, P. (2022). Preeclampsia. New England Journal of Medicine, 386(19), 1817–1832. https://doi.org/10.1056/NEJMra2109523 Cited by: 310

7.     Turchiano, M., & Tsioufis, C. (2022). 2022 ESC Guidelines on cardiovascular disease assessment and management in pregnancy. European Heart Journal, 43(35), 3325–3400. https://doi.org/10.1093/eurheartj/ehac255 Cited by: 290

Rolnik, D. L., Wright, D., Poon, L. C., O'Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., Molina, F. S., Persico, N., Jani, J. C., Plasencia, W., Papaioannou, G., Tenenbaum-Gavish, K., Meiri, H., Giz# Hypertensive Disorders in Pregnancy: Contemporary Pathophysiology, Clinical Management, Biomarker Advances, and Maternal-Fetal Outcomes